Get to know our clinical trials
Phase II clinical trial evaluating the safety and efficacy of repotrectinib in patients with ROS1-positive non-small cell lung cancer with active brain metastases.
THE PRIMARY OBJECTIVE OF THIS STUDY IS TO EVALUATE THE EFFICACY OF THE STUDY DRUG REPOTRECTINIB (A KINASE INHIBITOR THAT BLOCKS THE ACTIVITY OF THE ABNORMAL ROS1 PROTEIN) IN PATIENTS WITH NSCLC WHO HAVE A ROS1 ALTERATION AND ACTIVE BRAIN METASTASES.
Technical Summary
- PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF REPOTRECTINIB IN PATIENTS WITH ROS1-POSITIVE NON-SMALL CELL LUNG CANCER WITH ACTIVE BRAIN METASTASES (REPOSE STUDY).
- Code EudraCT: 2023-508112-35-00
- Protocol number: MEDOPP662
- Promoter: Medica Scientia Innovation Research SL
- Molecule/Drug: Repotrectinib
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.